CXCL8 and myeloid sarcoma: This conclusion is supported by the data that daclizumab treatment, which results in profound inhibition of CEL, inhibits CSF levels of IL-12p40 [6], CXCL13 [62] but not of IL-8 [6] and by high CSF IL-8 levels in non-MS OIND subjects.